Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies

Israel Franco*, Piet Hoebeke, Małgorzata Baka-Ostrowska, David Bolong, Leon Davies, Ellen Dahler, Robert Snijder, Otto Stroosma, Frank Verheggen, Donald Newgreen, Brigitte Bosman, Johan Vande Walle

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies'. Together they form a unique fingerprint.

Medicine & Life Sciences